Paradigm Biopharmaceuticals Future Growth

Future criteria checks 0/6

Paradigm Biopharmaceuticals is forecast to grow earnings at 8.8% per annum. EPS is expected to grow by 56.9% per annum.

Key information

8.8%

Earnings growth rate

56.9%

EPS growth rate

Biotechs earnings growth	15.3%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	08 May 2024

Recent future growth updates

Recent updates

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Aug 22

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Apr 17

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Sep 21

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Jun 20

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Dec 02

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Jun 07

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Feb 22

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

Jan 24

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Dec 28

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Nov 29

Earnings and Revenue Growth Forecasts

ASX:PAR - Analysts future estimates and past financials data (AUD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
6/30/2024	N/A	-59	-66	-66	N/A
3/31/2024	0	-64	-72	-72	N/A
12/31/2023	0	-69	-78	-78	N/A
9/30/2023	0	-60	-62	-62	N/A
6/30/2023	N/A	-52	-45	-45	N/A
3/31/2023	0	-48	-39	-39	N/A
12/31/2022	0	-44	-33	-33	N/A
9/30/2022	0	-42	-33	-33	N/A
6/30/2022	0	-39	-32	-32	N/A
3/31/2022	0	-40	-32	-32	N/A
12/31/2021	0	-41	-32	-32	N/A
9/30/2021	0	-37	-34	-34	N/A
6/30/2021	0	-34	-35	-35	N/A
3/31/2021	0	-31	-29	-29	N/A
12/31/2020	-1	-28	-24	-23	N/A
9/30/2020	0	-20	-17	-17	N/A
6/30/2020	N/A	-12	-10	-10	N/A
3/31/2020	2	-14	-10	-10	N/A
12/31/2019	4	-16	-10	-10	N/A
9/30/2019	3	-16	-8	-8	N/A
6/30/2019	3	-16	-6	-6	N/A
3/31/2019	3	-11	-7	-7	N/A
12/31/2018	3	-7	-7	-7	N/A
9/30/2018	3	-7	-6	-6	N/A
6/30/2018	3	-6	-6	-6	N/A
3/31/2018	2	-6	N/A	-4	N/A
12/31/2017	2	-5	N/A	-3	N/A
9/30/2017	2	-5	N/A	-4	N/A
6/30/2017	2	-4	N/A	-4	N/A
3/31/2017	2	-4	N/A	-5	N/A
12/31/2016	1	-4	N/A	-6	N/A
9/30/2016	1	-4	N/A	-5	N/A
6/30/2016	1	-3	N/A	-4	N/A
3/31/2016	1	-3	N/A	-3	N/A
12/31/2015	0	-2	N/A	-1	N/A
9/30/2015	0	-2	N/A	-1	N/A
6/30/2015	N/A	-2	N/A	-1	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: PAR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PAR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PAR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if PAR's revenue is forecast to grow faster than the Australian market.

High Growth Revenue: Insufficient data to determine if PAR's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if PAR's Return on Equity is forecast to be high in 3 years time

Paradigm Biopharmaceuticals Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Price target increased to AU$2.20

Forecast to breakeven in 2024

Price target decreased to AU$2.64

Price target increased to AU$4.49

Recent updates

Donna Skerrett Steps Down from Position as an Executive Director on the Board of Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd Plans to Submit the Finalized Protocol for Its Phase 3 Clinical Trial

Non-Executive Director recently bought AU$73k worth of stock

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 19, 2024

New minor risk - Profitability

Insufficient new directors

New minor risk - Share price stability

New minor risk - Shareholder dilution

New minor risk - Market cap size

New minor risk - Share price stability

Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately

Consensus EPS estimates fall from profit to AU$0.18 loss

Forecast breakeven date pushed back to 2025

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Paradigm Biopharmaceuticals (ASX:PAR) Is In A Strong Position To Grow Its Business

Founder recently bought AU$76k worth of stock

Here's Why We're Not At All Concerned With Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee (DMC) for the Pivotal Para_OA_002 Clinical Trial

Founder recently bought AU$62k worth of stock

Paradigm Biopharmaceuticals Limited Announces Executive Changes

Price target increased to AU$2.20

Paradigm Biopharmaceuticals Limited Announces an Abstract on Paradigm's Phase 2 Clinical Trial Evaluating Injectable Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Announces First UK Subject Randomised and Dosed for the Pivotal Phase 3 Trial for the Treatment of Pain Associated with Knee OA

Paradigm Biopharmaceuticals Ltd Announces Successful Primary Endpoint in Phase 2 Trial

Paradigm Biopharmaceuticals Ltd Provides an Update on the Ongoing Multi-Centre Double-Blind Randomised Phase 2 Study Comparing PPS to Placebo in Mucopolysaccharidosis Type VI (MPS-VI) Patients

Paradigm Biopharmaceuticals Limited, Annual General Meeting, Nov 18, 2022

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Appoints Abby Macnish as Interim Company Secretary

Paradigm Biopharmaceuticals Ltd Announces MPS Clinical Program Update and Paradigm to Present At the International Conference on Lysosomal Diseases

Paradigm Biopharmaceuticals Limited Reports Important Global Progress for the Para_Oa_002 Phase 3 Clinical Trial Evaluating Zilosul® for Osteoarthritis

Paradigm Biopharmaceuticals Limited Announces PARA_OA_008 Study Evaluating Zilosul® Mechanism and Disease Modifying Effects Completes Recruitment

Forecast to breakeven in 2024

Here's Why We're Not Too Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn Situation

Paradigm Biopharmaceuticals Limited Announces Chief Executive Officer Changes

Paradigm Biopharmaceuticals Limited Doses First US Subjects Under Phase 3 Trial

Price target decreased to AU$2.64

U.S. Food and Drug Administration Grants Fast Track Designation for Paradigm Biopharmaceuticals Ltd of Phase 3 Program

Founder & Non-Executive Chairman recently bought AU$51k worth of stock

Price target increased to AU$4.49

Consensus forecasts updated

No longer forecast to breakeven

Paradigm Biopharmaceuticals Limited Announces First Subjects Randomised and Dosed in Para_0A_002 Phase 3 Study in Australia

Paradigm Biopharmaceuticals Ltd Reports Postive Topline Results in Heart Failure Model

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Limited Reports Preliminary Results from Phase 2 Mps I Study

Paradigm Biopharmaceuticals Limited Announces First MPS-VI Patient Dosed Under Phase 2 Trial in Brazil Investigating PPS for the Treatment of MPS-VI

Paradigm Biopharmaceuticals Limited Receives Feedback from US FDA on IND Submission

Paradigm Biopharmaceuticals Limited Announces Australian Ethics Approval for Paradigm's ARA_OA_002 Pivotal Phase 3 Clinical Trial in Participants with Knee OA

Paradigm Biopharmaceuticals Limited Makes Progress with Investigational New Drug Application

Consensus EPS estimates increase to -AU$0.15

Paradigm Biopharmaceuticals Limited Receives Key Regulatory Approvals for MPS VI Study

Companies Like Paradigm Biopharmaceuticals (ASX:PAR) Are In A Position To Invest In Growth

Paradigm Biopharmaceuticals Ltd Receives First Revenue Through Physician Prescription of Zilosul to Patients Via the TGA SAS

Paradigm Biopharmaceuticals Ltd Provides an Update on its IND Application to the Us Food and Drug Administration

Paradigm Biopharmaceuticals Limited Updates Phase 2A, Randomised, Double-Blind, Placebo- Controlled Study

Analysts lower EPS estimates to -AU$0.17

New 90-day low: AU$2.28

Is Paradigm Biopharmaceuticals Limited (ASX:PAR) Trading At A 46% Discount?

Paradigm Biopharmaceuticals Ltd Announces It Has Received Ethics Approval for Its Phase 2 Clinical Trial to Evaluate the Treatment Effects of Pentosan Polysulfate Sodium

Paradigm Biopharmaceuticals Limited Appoints Helen Fisher as Non-Executive Director and Chair of the Audit and Risk Committee

Paradigm Biopharmaceuticals Ltd Reports Ongoing Data Update on Patients Who Received Zilosul Under the Therapeutic Goods Administration (TGA) Special Access Scheme

We're Not Worried About Paradigm Biopharmaceuticals' (ASX:PAR) Cash Burn

New 90-day low: AU$2.38

New 90-day low: AU$2.44

Did You Participate In Any Of Paradigm Biopharmaceuticals' (ASX:PAR) Incredible 811% Return?

Paradigm Biopharmaceuticals Ltd Receives the Written Response from the Type-C meeting with the US Food and Drug Administration (FDA) regarding Zilosul® for the Treatment of Osteoarthritis

When Will Paradigm Biopharmaceuticals Limited (ASX:PAR) Turn A Profit?

Paradigm Biopharmaceuticals Limited Announces Resignation of Chris Fullerton as Non- Executive Director